Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CMB-401
- Development stage
- Discontinued
- Lead developer
- Pfizer
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
**CMB-401** is an investigational, discontinued **MUC1-targeted antibody-drug conjugate** developed from the humanized anti-polymorphic epithelial mucin antibody hCTM01 linked through an amide linker to the enediyne cytotoxin calicheamicin. The antibody component targets Mucin-1 on epithelial tumor cells, supporting cellular internalization and delivery of calicheamicin, which induces DNA damage. CMB-401 reached phase 2 testing in recurrent platinum-sensitive epithelial ovarian carcinoma, but no partial responses were observed among evaluable patients and further development was discontinued. ([ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11034231/))
- Other names
- hCTM01-calicheamicinhCTM-01-calicheamicinhCTM 01-calicheamicinhCTMO1-calicheamicinhCTMO-1-calicheamicinhCTMO 1-calicheamicin
02
Targets
MUC1 (Mucin-1 Antigen)DNA
Beyond the preview
Go deeper on CMB-401.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CMB-401.